Mexicor® reduces manifestations of oxidative stress, inhibiting free radical peroxide oxidation of lipids and increasing the activity of the antioxidant system of enzymes. Mexicor® improves cellular energy metabolism, activating the energy-synthesizing functions of mitochondria, enhancing compensatory activation of aerobic glycolysis and reducing the degree of inhibition of oxidative processes in the Krebs cycle. The energosynthesizing effect of the drug is associated with an increase in the delivery and consumption of succinate cells, the realization of the phenomenon of rapid oxidation of succinic acid with succinate dehydrogenase,as well as activation of the mitochondrial respiratory chain. When the Mexocor® preparation is dissociated in the cell to succinate and the 3-hydroxypyridine derivative (base), the base exhibits an antioxidant effect, stabilizing the cell membranes and restoring functional activity of cells. Reduces the viscosity of the cell membrane, increases its fluidity and has a modulating effect on membrane-bound enzymes (calcium independent phosphodiesterase, adenylate cyclase, acetylcholinesterase, ion channels and receptor complexes, which contributes to the preservation of the structural and functional integrity of biomembranes, improves neurotransmitter transport and synaptic transmission. brain, microcirculation and rheological properties of blood, reduces platelet aggregation.
It improves the functional state of the ischemic myocardium, the contractile function of the heart, and also reduces the manifestations of systolic and diastolic dysfunction of the left ventricle. In conditions of coronary insufficiency increases the collateral blood supply of the ischemic myocardium and activates the energy-synthesis processes inzone of ischemia, which contributes to maintaining the integrity of cardiomyocytes and maintaining their functional activity. Effectively restores myocardial contractility in reversible cardiac dysfunction, which represents a significant reserve of increasing the contractility of the heart in patients with coronary heart disease complicated by heart failure.
In patients with stable angina, stress increases tolerance to physical activity and antianginal activity of nitro drugs, improves the rheological properties of blood. Adding Mexocor® to standard therapy for coronary heart disease improves the clinical state of patients, increasing exercise tolerance and improving quality of life.
Mexicore® Stabilitysupperuet membwounded, structureuri jarhistory wall, inhibitionruet platelet aggregation normalize microcirculation disturbances in the early stages of atherogenesis has hypolipidemic effect, reduces total cholesterol and low density lipoprotein (LDL).
Mexicor® has a neuroprotective effect on the functional activity and metabolism of the ischemic brain,increases the stability of blood circulation in the brain under conditions of hypoperfusion, prevents a decrease in the blood flow of the brain in the reperfusion period after ischemia. The drug contributes to adaptation to the damaging effect of ischemia, inhibiting the depletion of carbohydrate reserves, blocking the postischemic decline in the utilization of glucose and oxygen by the brain and preventing the progressive accumulation of lactate. At the same time, the indices of autoregulatory reactions of cerebral vessels improve.
Mexicor® has nootropic properties, it prevents and reduces learning and memory disruptions arising from acute and chronic vascular diseases of the brain, with mild and moderate cognitive impairments of various genesis, has an antioxidant effect, increases concentration and operability.
Inclusion of the preparation Mexicor ® in the complex therapy of patients with acute impairment of cerebral circulation reduces the severity of clinical manifestations of stroke and improves the course of the rehabilitation period.
Mexicor ® has a selective, not accompanied by sedation and miorelaxation, anxiolytic action, eliminates anxiety, fear, tension, anxiety,improves adaptation and emotional status.